PsyBio Therapeutics (PsyBio Therapeutics) EBIT : $-2.84 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is PsyBio Therapeutics EBIT?

PsyBio Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2023 was $-0.18 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was $-2.84 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PsyBio Therapeutics's annualized ROC % for the quarter that ended in Jun. 2023 was -241.07%. PsyBio Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -817.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PsyBio Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -334.86%.

PsyBio Therapeutics EBIT Historical Data

The historical data trend for PsyBio Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PsyBio Therapeutics EBIT Chart

PsyBio Therapeutics Annual Data

Trend

Dec21

Dec22

EBIT

-11.02

-4.87

PsyBio Therapeutics Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EBIT	Get a 7-Day Free Trial							-1.43	-0.92	-0.94	-0.81	-0.18

Competitive Comparison of PsyBio Therapeutics's EBIT

For the Biotechnology subindustry, PsyBio Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PsyBio Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PsyBio Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PsyBio Therapeutics's EV-to-EBIT falls into.

PsyBio Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.84 Mil.

PsyBio Therapeutics (OTCPK:PSYBF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PsyBio Therapeutics's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-0.628 * ( 1 - 0% )	/	( (0.209	+	0.312)	/ 2 )
=	-0.628	/	0.2605
=	-241.07 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.3	-	1.822	-	( 0.069	-	max(0, 1.932	-	0.201	+	0.069	))
=	0.209

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.283	-	1.836	-	( 0.012	-	max(0, 1.971	-	0.106	+	0.012	))
=	0.312

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

PsyBio Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.728	/	( ( (0.089 + max(-1.704, 0))	+	(0.089 + max(-1.781, 0)) )	/	2 )
=	-0.728	/	( ( 0.089	+	0.089 )	/	2 )
=	-0.728	/	0.089
=	-817.98 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.132)	-	(1.822	+	0	+	0.014)
=	-1.704

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.094)	-	(1.836	+	0	+	0.039)
=	-1.781

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PsyBio Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-2.843	/	0.849
	=	-334.86 %

PsyBio Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of PsyBio Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

PsyBio Therapeutics (PsyBio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PsyBio Therapeutics Corp (OTCPK:PSYBF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

PSYB:Canada

Address

4400 Sample Road, Suite 138, Coconut Creek, FL, USA, 33073

Website

https://www.psybiolife.com

PsyBio Therapeutics Corp is a biotechnology company. The company is engaged in the development of drugs intended for the treatment of mental illness and neurological disorders.

PsyBio Therapeutics (PsyBio Therapeutics) Headlines

From GuruFocus

PsyBio Therapeutics to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th

By PRNewswire PRNewswire • 10-11-2021

PsyBio Announces Second Quarter Financial Results of Leo Acquisition Corp.

By GlobeNewswire GlobeNewswire • 03-02-2021

PsyBio Therapeutics Announces Uplisting to OTCQB Venture Market

By PRNewswire PRNewswire • 07-14-2021